(Q24194293)

2

0 references

John K MacDonald

3

0 references

John WD McDonald

4

0 references

Nilesh Chande

Cochrane Database of Systematic Reviews

5

0 references

publication date

26 August 2014

0 references

published in

0 references

cites work

A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006884.PUB3

Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006884.PUB3

Combining infliximab with methotrexate for the induction and maintenance of remission in refractory Crohn's disease: a controlled pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006884.PUB3

Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn's disease: a randomised, investigator-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006884.PUB3

Methotrexate for Crohn's disease: experience in a district general hospital

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006884.PUB3

Bioavailability of oral vs. subcutaneous low-dose methotrexate in patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006884.PUB3

Mucosal healing with methotrexate in Crohn's disease: a prospective comparative study with azathioprine and infliximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006884.PUB3

[Sustaining remission in Crohn disease with methotrexate--a placebo controlled study]

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006884.PUB3

Efficacy and tolerability of methotrexate therapy for refractory Crohn's disease: a large single-centre experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006884.PUB3

Low-dose oral methotrexate for maintaining Crohn's disease remission: where we stand

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006884.PUB3

Pharmacokinetic profiles for oral and subcutaneous methotrexate in patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006884.PUB3

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006884.PUB3

Pharmacokinetics of subcutaneous methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006884.PUB3

Systemic and intestinal pharmacokinetics of methotrexate in patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006884.PUB3

GRADE: an emerging consensus on rating quality of evidence and strength of recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006884.PUB3

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006884.PUB3

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006884.PUB3

American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006884.PUB3

Methotrexate for induction of remission in refractory Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006884.PUB3

Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006884.PUB3

Methotrexate in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006884.PUB3

Corticosteroids for maintenance of remission in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006884.PUB3

Methotrexate for maintenance of remission in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006884.PUB3

Methotrexate for the Treatment of Crohn's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006884.PUB3

Methotrexate for the maintenance of remission in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006884.PUB3

7 January 2021

A randomized dose-response and pharmacokinetic study of methotrexate for refractory inflammatory Crohn's disease and ulcerative colitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006884.PUB3

7 January 2021

A study of parenteral use of methotrexate in rheumatic conditions

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006884.PUB3

7 January 2021

6-mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006884.PUB3

7 January 2021

Long-term methotrexate for Crohn's disease: safety and efficacy in clinical practice

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006884.PUB3

7 January 2021

Long-term results with azathioprine therapy in patients with corticosteroid-dependent Crohn's disease: open-label prospective study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006884.PUB3

7 January 2021

Methotrexate and maintenance of remission in Crohn's disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006884.PUB3

7 January 2021